Goldman Sachs resumed coverage of Amylyx (AMLX) with a Buy rating and $10 price target suggesting 58% upside. The firm has a positive view on avexitide for the treatment of post-bariatric surgery hypoglycemia. It sees a potential blockbuster opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects
- Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
- Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Breakthrough for Post-Bariatric Hypoglycemia
- Amylyx initiated with a Buy at Guggenheim on ‘blockbuster potential’
- Amylyx initiated with a Buy at Guggenheim